Zenas BioPharma Inc. (ZBIO)
NASDAQ: ZBIO
· Real-Time Price · USD
18.62
-1.66 (-8.19%)
At close: Sep 25, 2025, 3:59 PM
18.62
0.00%
After-hours: Sep 25, 2025, 04:17 PM EDT
-8.19% (1D)
| Bid | 18.5 |
| Market Cap | 784.09M |
| Revenue (ttm) | 15M |
| Net Income (ttm) | -176.97M |
| EPS (ttm) | -12.29 |
| PE Ratio (ttm) | -1.52 |
| Forward PE | -4.38 |
| Analyst | Buy |
| Dividends | n/a |
| Ask | 20.47 |
| Volume | 244,453 |
| Avg. Volume (20D) | 204,093 |
| Open | 19.70 |
| Previous Close | 20.28 |
| Day's Range | 18.36 - 19.91 |
| 52-Week Range | 5.83 - 26.25 |
| Beta | -2.30 |
| Ex-Dividend Date | n/a |
About ZBIO
undefined
Industry n/a
Sector n/a
IPO Date n/a
Employees NaN
Stock Exchange n/a
Ticker Symbol ZBIO
Website n/a
Analyst Forecast
According to 0 analyst ratings, the average rating for ZBIO stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.
Stock ForecastsZenas BioPharma Inc. is scheduled to release its earnings on
Nov 11, 2025,
before market opens.
Analysts project revenue of ... Unlock content with Pro Subscription
Analysts project revenue of ... Unlock content with Pro Subscription
1 month ago · seekingalpha.com
Zenas Biopharma: A Risky Buy On Upcoming Data Readouts In IgG4, MSZenas BioPharma, Inc.'s Obexelimab offers a differentiated, non-depleting B-cell inhibition approach, with promising Phase 2 data in IgG4 and upcoming pivotal catalysts in 2025. The lead asset's block...